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Abstract: The increasing extension in life expectancy of human beings in developed countries is
accompanied by a progressively greater rate of degenerative diseases associated with lifestyle and
aging, most of which are still waiting for effective, not merely symptomatic, therapies. Accordingly, at
present, the recommendations aimed at reducing the prevalence of these conditions in the population
are limited to a safer lifestyle including physical/mental exercise, a reduced caloric intake, and a
proper diet in a convivial environment. The claimed health benefits of the Mediterranean and Asian
diets have been confirmed in many clinical trials and epidemiological surveys. These diets are
characterized by several features, including low meat consumption, the intake of oils instead of fats
as lipid sources, moderate amounts of red wine, and significant amounts of fresh fruit and vegetables.
In particular, the latter have attracted popular and scientific attention for their content, though in
reduced amounts, of a number of molecules increasingly investigated for their healthy properties.
Among the latter, plant polyphenols have raised remarkable interest in the scientific community; in
fact, several clinical trials have confirmed that many health benefits of the Mediterranean/Asian diets
can be traced back to the presence of significant amounts of these molecules, even though, in some
cases, contradictory results have been reported, which highlights the need for further investigation. In
light of the results of these trials, recent research has sought to provide information on the biochemical,
molecular, epigenetic, and cell biology modifications by plant polyphenols in cell, organismal, animal,
and human models of cancer, metabolic, and neurodegenerative pathologies, notably Alzheimer’s
and Parkinson disease. The findings reported in the last decade are starting to help to decipher the
complex relations between plant polyphenols and cell homeostatic systems including metabolic and
redox equilibrium, proteostasis, and the inflammatory response, establishing an increasingly solid
molecular basis for the healthy effects of these molecules. Taken together, the data currently available,
though still incomplete, are providing a rationale for the possible use of natural polyphenols, or their
molecular scaffolds, as nutraceuticals to contrast aging and to combat many associated pathologies.
Keywords: plant polyphenols; hormesis; autophagy; Mediterranean diet; olive oil; curcumin;
resveratrol; oleuropein; hydroxytyrosol; epigallocathechin; epigenetics
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1. Introduction
Human beings in advanced countries are experiencing an increasing extension in life expectancy,
yet at the cost of a progressively greater prevalence of a number of diseases associated with lifestyle
and age. The latter include widespread pathologies such as cancer, metabolic disease such as type
2 diabetes mellitus (T2DM), hepatitis and the metabolic syndrome (MetS), cardiovascular diseases
(CVDs), and amyloid diseases, both systemic and neurodegenerative, particularly Alzheimer’s (AD)
and Parkinson (PD) diseases. Among the latter pathologies, amyloid diseases, both the sporadic and
the early onset familial forms, are substantially intractable. In particular, most sporadic amyloidoses
are characterized by slow progression, often covering several decades, and their clinical signs appear
only at mid- or old age, when they are irreversible due to conspicuous cell loss. It is then evident that
the absence of fully reliable early diagnostic tools and of resolutive therapies, particularly in the case of
amyloid diseases, calls for prevention in the role of best approach to face these pathological conditions.
Following the considerations reported above, it is not surprising that research has progressively
shifted from a “cure” to “prevention” focus, in addition to the “drugs”, and the “lifestyle” concept,
including “diet”, and hence “food”. Many epidemiological and observational studies support the idea
that the Mediterranean diet (MD) and the Asian diet are associated with “safe” aging, with a reduced
prevalence of diseases associated with aging including CVDs, cancer, and cognitive decline [1]. The
MD is the result of a complex socio-economic development of the Mediterranean populations in which
agricultural, social, territorial, and environmental practices represent a heritage intimately associated
with their culture and lifestyle that has been passed through several generations over many centuries.
The great value of the MD and the associated lifestyle has been recognized by the “Organizzazione
delle Nazioni Unite per l’Educazione, la Scienza e la Cultura“ (UNESCO) that, since November 2010,
has inscribed the MD in the list of the intangible cultural heritage of humanity (https/ich.unesco.org/).
Recently, the “Mediterranean Diet Foundation Expert Group” has proposed a new MD pyramid [2]; the
latter, besides confirming the importance of the daily assumption of substantial amounts of vegetables,
fruits, legumes, grains, nuts, seeds, and, in particular, of a moderate intake of red wine and of extra
virgin olive oil (EVOO) as the main lipid source, also emphasizes a healthy lifestyle where, in addition
to caloric restriction (CR), frugality, moderation, adequate rest, conviviality, culinary activities, and
physical exercise play an important role.
A key aspect of the MD is the high assumption of phytonutrients (particularly vitamins and
plant phenols) that, by themselves, interfere with multiple signaling pathways involved in protein
homeostasis, DNA repair, metabolism regulation, and antioxidant defenses that, in most cases, recall
CR [3,4]. Many available data and population studies suggest that greater adherence to the MD reduces
metabolic pathologies and aging-associated deterioration; these data have been further supported
by a number of clinical trials carried out by administering foods enriched in specific polyphenols to
patients at cardiovascular or neurodegeneration risk, suffering from metabolic diseases, or affected
by some forms of cancers (see below). Biophenols are found in many foods of plant origin that are
key components of the MD and the Asian diet; these include red wine, EVOO, green tea, spices,
berries, and aromatic herbs that ensure a continuous daily moderate intake of these substances during
lifespan. Hence, the presence of substantial amounts of polyphenols in the diet may provide a rationale
for the results of the large number of population studies and clinical trials supporting the idea that
an association does exist between dietary practices, their content in polyphenols, and a significant
reduction of the incidence of many aging-associated diseases [5].
The studies carried out during the last decade have highlighted the fact that, in the case of amyloid
diseases and several other aging-associated pathologies, plant polyphenols do not simply affect a single
step of the pathogenesis of these diseases such as the aggregation path of the involved protein/peptide,
the inflammatory response, the alteration of the proteostatic network, and/or the oxidative stress;
rather, the biological and functional features of their positive outcomes result from multi-target effects
that restore several altered homeostatic systems in the cells and tissues where impaired metabolism
or protein/peptide aggregation occur. Moreover, these molecules share key chemical features that, at
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least in part, explain why most of them, although chemically different, induce similar effects. Recent
research is increasingly shedding light in the biochemical, cellular, and epigenetic modifications
produced by a number of investigated plant polyphenols, with special emphasis on the olive ones,
and the ensuing modulation of key cellular processes such as metabolic/energetic/redox homeostasis,
proteostasis, signaling, and control of oxidative stress and of gene expression. These data are providing
the knowledge needed to fully understand the beneficial effects of the MD and the Asian diet and the
importance of plant polyphenols for human wellness and as possible tools useful in disease prevention
and, possibly, therapy.
Here, we summarize the results of the studies on a number of plant polyphenols, with particular
emphasis on those found in the olive leaves and drupes and in the EVOO, particularly oleuropein
aglycone (OLE) and hydroxytyrosol (HT). We also provide data on the population surveys and clinical
trials supporting the beneficial effects of the MD, its content in fruit, vegetables, herbs, and EVOO,
and the intake of these molecules. We also focus the main molecular mechanisms by which plant
polyphenols ensure protection against a number of age-related pathologies, in light of the recently
proposed hormetic theory (see below); the molecular determinants underlying such protection both
in biological models such as cultured cells and animals and the most recent advances towards their
possible use in prevention and, possibly, as co-adjuvants in clinical treatment of neurodegenerative
diseases, CVDs, cancer, T2DM, and the MetS are also discussed.
2. Polyphenols: Important Players of the Mediterranean/Asian Diets
Natural biophenols are a wide group of molecules (over 8000 described so far) found only
in the plant kingdom; their molecules display one or more aromatic rings carrying one or more
hydroxyl groups; these molecules display remarkable antioxidant power and are produced as
secondary metabolites by the plant for protection against the attack by bacteria, fungi, and insects
(phytoalexins) [1]. Plant polyphenols include non-flavonoids or flavonoids; the latter are further
divided into flavonols, flavononols, flavones, anthocyanins, procyanidins, phenolic acids, stilbenes,
and tannins depending on the number of hydroxyls in the molecule and on the nature and the position
of other substituents [6]. The natural phenols most studied for their healthy properties ar curcumin, a
phenolic acid found in the rhizome of Curcuma longa Linn (family Zingiberaceae) and a component of
the curry; epigallocathechins, notably epigallocatechin-3-gallate (EGCG), the flavanol found in green
tea; resveratrol (3,5,4′-trihydroxy-trans-stilbene), a stilbene found in grapes and in red wine; quercetin
and myricetin, flavonols present in tea, onions, cocoa, red wine, and in Ginkgo biloba extracts. Many
other plant phenols or their metabolic derivatives have also been investigated, yet with variable results;
these include tannic, ellagic, ferulic, nordihydroguaiaretic and caffeic acid, morin, rutin, apigenin,
baicalein, kaempferol, fisetin, luteolin, rottlerin, malvidin, piceatannol, and silibinin.
More recently, particular interest has been dedicated to the polyphenols present abundantly in
the leaves and in the ripening fruits of the olive tree (Olea europaea); including flavonols, lignans
iridoids, and their glycosides. Iridoids are monoterpenes containing a cyclopentane ring fused to
a six-atom heterocycle with an oxygen atom, whereas the molecules where the cyclopentane ring
is interrupted are indicated as secoiridoids. The most abundant polyphenols found in the EVOO
include the secoiridoids oleuropein and ligstroside, both in the glycated and in the aglycone forms,
and their main metabolites: The phenolic alcohols tyrosol (p-hydroxyphenylethanol, p-HPEA) and
hydroxytyrosol (3,4-dihydroxyphenylethanol, 3,4-DHPEA), oleacein, and oleocanthal. Oleuropein
confers the bitter taste to the olive leaves, drupes, and EVOO, whereas oleocanthal produces the
burning sensation in the back of the throat when consuming EVOO [7,8]. Phenolic concentration in
plants depends on several variables; in the olive tree, and hence in the EVOO, these include (i) olive
cultivar and stage of ripening [9]; (ii) environmental cues (altitude, cultivation practices, meteorological
factors, and irrigation); (iii) technological aspects such as extraction conditions (temperature and others)
and systems to separate oil from olive pastes; and (iv) storage conditions and time, due to spontaneous
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oxidation, and deposition of suspended water droplets with their content of polyphenols [10]. At the
best, polyphenol content in the EVOO can exceed 60 mg/100 g.
Plant polyphenols have been considered for their remarkable antioxidant properties; however, their
effects go well beyond this property. In fact, plant polyphenols have been shown to possess beneficial
effects against aggregation of peptides/proteins into amyloid assemblies, a process involved in several
amyloid diseases, particularly T2DM, AD, and PD, thus reducing the load of intra- or extracellular
deposits [1]. T2DM is characterized by aggregates of the peptide amylin in insulin-secreting pancreatic
β-cells; AD results from the extracellular amyloid aggregation of the Aβ peptide (mostly Aβ1–42)
in senile and neuritic plaques and the intracellular aggregation into neurofibrillary tangles of tau
protein; these aggregates are found in specific brain areas, notably the hippocampus and the pre-frontal
cortex. PD results mostly from the aggregation of α-synuclein into intracellular Lewy bodies found in
the neurons of the mesencephalic substantia nigra. Actually, olive polyphenols, notably OLE and its
main metabolite, HT, have been reported to be effective against amyloid aggregation and the ensuing
pathologic effects in T2DM [11,12], AD [13–19] and, possibly, in PD [20,21] and other amyloidoses.
Plant polyphenols, including those enriched in EVOO, have also been reported to reduce insulin
resistance and to improve impaired glucose homeostasis, two main signs of T2DM. Considering that
increasing evidence supports a strong link between diabetes (mainly T2DM) and neurodegeneration
associated with AD [22,23], it is conceivable that many plant polyphenols can interfere with both
pathologies at similar molecular levels.
The beneficial effects of plant preparations and derivatives, including, in the case of olive, oil and
leaf extracts, have already been known for the last couple of centuries and have been scientifically
investigated over the recent several decades; these researches have progressively led to a focus
on the multi-target activity and health properties of plant polyphenols, including the anti-amyloid
aggregation, antioxidant, antimicrobial, antihypertensive, hypoglycemic, and vasodilator effects. The
antioxidant power has been shown to involve modulation of oxidative pathways [2], direct action on
enzymes, proteins, receptors, and several types of signaling paths [3,4], as well as the interference
with epigenetic modifications of chromatin [24] (see below). The clinical significance of the beneficial
properties of plant polyphenols was first reported in 1950 [25], leading to the inclusion in the European
Pharmacopoeia (Ph. Eur.) of the 80% alcoholic extract of olive leaves, containing oleuropein, HT, caffeic
acid, tyrosol, apigenin, and verbascoside [26,27]. Biophenols can also be used to develop new drugs
useful to combat chronic inflammatory conditions, the risk of thrombosis, CVD-related states such as
atherosclerosis [28], cancer [29], also in combination with anti-cancer drugs [30], as well as to reduce
amyloid deposition associated with T2DM and aging-related states such as neurodegeneration [1,31]
(Figure 1). Finally, the molecular scaffolds of plant polyphenols are also investigated to develop new
molecules potentially exploitable in disease prevention and therapy [32].
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The beneficial effects of olive and other plant polyphenols can be hindered by the reduced
bioavailability of the latter following reduced intestinal absorption and their rapid biotransformation
in the organism; in addition, chemical modifications of many polyphenols by gut microbiota
further reduces their bioavailability and biological efficacy [33]. Several strategies to overcome
reduced bioavailability have been proposed, including encapsulation within nanoparticles [34],
self-microemulsifying formulations [35], and others (reviewed in [36]). Yet, several studies have
shown that many plant polyphenols, including EVOO polyphenols, are absorbed, although in reduced
amount, by humans and distributed, in part, to organs and tissues before completion of their secondary
metabolism, degradation, and excretion [37–39]. Moreover, some OLE metab lites, notably HT, arising
mainly from acid hydrolysis in the stomach, have been found in the brai of TgCRND8 mice and
rats after an acute oral dministration of either OLE or HT, which supports the ability of OLE and
some of its derivative , including HT, to cross the blood–brain barrier [40,41]. In particular, convincing
evidence indicates that HT is dose-dependently bioavailable; it is su st ntially (40%) a sorbed and
reaches maximum concentration in plasma after 5–30 min from EVOO ingestion, with a calculated
total bioavailability around 10% due to metabolic modifications in the gut and in the organism through
phase II conjugation reactions [42]. Thus, in spite of reduced information on many aspects of their
pharmacokinetics, pharmacodynamics, and metabolic modifications by gut microbiota and in the
organism, oral assumption of plant polyphenols results in partial absorption and distribution to the
whole organism (reviewed in [43]).
3. The Beneficial Effects of Plant Polyphenols Are Supported by Population Studies and Clinical
Trials
A wealth of currently available data arising from population studies suggest that greater adherence
to the MD improves healthy aging by reducing the risk of cardiovascular diseases (CVDs), metabolic
pathologies, cancer, and aging-associated mental deterioration; in particular, it enhances cognitive
function and reduces both the risk of developing mild cognitive impairment and of its conversion to
AD [44,45]. The beneficial effects of the MD have been related to the presence, in the latter, of many
polyphenols, particularly those enriched in fruits and vegetables, in red wine, and in EVOO (reviewed
in [1,43]). The importance of the content of polyphenols (EGCG, OLE, HT, resveratrol, curcumin,
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quercetin, morin, myricetin, and many others) in the MD has been confirmed by many population
studies and clinical trials.
Over 60 years ago, the first large-population study on the diet–health relation, the “Seven Countries
Study”, reported quite a low rate of cardiovascular mortality in Crete farmers, though in the presence
of a large intake of lipids, and related that finding to their MD (reviewed in [46]). Some years later,
other studies confirmed and extended these results. The “Lyon Diet Heart Study” further supported
the MD–myocardial infarction relation, leading to the conclusion that the MD may delay considerably,
up to 46 months, the rate of recurrence [47]. The “Three-City Study”, conducted on 7000 elderly
subjects, is one of the most cited studies on the protection by olive oil against neurodegeneration and
cognitive decline. The results of the study, published in 2009, showed a lower rate of cognitive deficit
in subjects whose diet was characterized by the presence of variable amounts of olive oil with respect
to the subjects using other lipids [48].
More recently, the randomized “PREvención con DIeta MEDiterránea” (PREDIMED) and
PREDIMED-NAVARRA studies have been conducted in Spain on subjects at high cardiovascular risk
(477 and 522 participants, respectively) [49–51]. In particular, the PREDIMED-NAVARRA study was
originally carried out on high-cardiovascular-risk asymptomatic subjects (187 people, 67 years mean
age) on MD supplemented with olive oil, with nuts, or at control diet to test the effect of the two
types of MD on the progression of subclinical carotid atherosclerosis. The results showed significant
improvement in mean intima-media thickness with regression of carotid atherosclerosis after one year
in people on either MD [52]. The PREDIMED study was a primary prevention trial originally designed
to test the long-term effects of the MD on the incidence of CVDs in people at high cardiovascular risk;
the trial suggested that olive oil consumption matches reduced risk and mortality for CVDs [53,54].
The same cohort was also checked for cognition, which was significantly improved in people following
an EVOO-enriched MD [49,51]. The study also investigated breast cancer incidence in the same
cohort, leading to the conclusion that the risk of developing cancer was reduced by 68% in the EVOO
group [55]. Finally, data from a subsample (n = 990) of the PREDIMED study showed that the MD
significantly decreased low-density lipoproteins (LDL) oxidation only when it was enriched in EVOO
with medium-high phenolic content [56].
More recently, a cross-sectional sampling population study was carried out among Spanish people
in 100 health centers, where 4572 individuals aged > 18 years, representative of the Spanish population,
were analyzed on the basis of their use of olive or sunflower oil. According to the study, the intake of
olive oil resulted as beneficial against several cardiovascular risk factors, particularly in obese people
with a sedentary lifestyle, impaired glucose tolerance, and insulin resistance [57]. Another study
carried out in the USA investigated the relation between intake of olive oil and incidence of T2DM; the
study followed 59,930 women (35–65 years) for 22 years from the Nurses’ Health Study and 85,157
women (26–45 years) from the NHS II with no diabetes, CVDs, or cancer at baseline. The results
indicated that a slightly lower risk of T2DM was associated with higher olive oil intake, whereas an
increased risk was associated with the assumption of other lipids in place of olive oil [58].
A very recent crossover study carried out with 25 healthy subjects randomly distributed
to a MD without EVOO or supplemented with 10 g EVOO/day concluded that EVOO reduces
post-prandial levels of LDL-cholesterol and glucose, further supporting the positive effects of the
MD against atherosclerosis [59]. Moreover, a small crossover trial (Trial number: ISRCTN09220811)
was conducted in the context of the “EUROLIVE” study with 200 participants who, after a two-week
washout, assumed 25 mL of olive oil with different phenolic content three times in a day for three
weeks. The results indicated a linear decrease of the oxidative stress markers ratio and of the total
cholesterol/HDL-cholesterol matching the content of polyphenols in olive oil [60]. A subset of the
same trial suggested protection against atherosclerosis [61]. Another subset of the study confirmed
that the phenolic content in olive oil increases human HDL functionality by favoring HDL-mediated
efflux of cholesterol from macrophages [62]. In another multicenter trial in Spain, 7447 participants
(55–80 years) at high cardiovascular risk, but with no CVD at enrollment, were assigned to a MD
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supplemented with EVOO, a MD supplemented with mixed nuts, or a control diet (with reduced fat).
The authors reported that the incidence of major cardiovascular events was lower in the participants
on an EVOO- or nut-supplemented MD than in those at a diet with reduced fat. [63].
In 2010, a study with 20 patients with the MetS showed that the acute intake of olive oil fortified
with olive polyphenols resulted in positive changes of the postprandial expression of disease-involved
genes in mononuclear cells from peripheral blood [64]. Studies were also carried out to determine
the effects of an acute administration of olive oil, particularly in the case of protection against
postprandial hyperlipidemia and the associated inflammation. Another research conducted on 20
obese subjects showed that oils rich in phenols reduced postprandial inflammation by lowering the
levels of pro-inflammatory cytokines and by activating nuclear factor κB (NF-κB) [65]. Some other
studies reported a remarkable delay in living day activities decline together with improved cognition,
psychopathology, and quality of life of the involved people [66–68]. Recently, a study carried out on 62
institutionalized elderly humans fed with EVOO showed a significant improvement of their redox
status, with positive effects on lipid profiles and total antioxidant capacity, significantly increased
activity of catalase in erythrocytes, and decreased activity of superoxide dismutase and glutathione
peroxidase [69]. Finally, a systematic review evaluated the effect of the intake of olive oil with high
or low polyphenol content on CVDs risk factors, as emerged in a number of clinical trials; the study
concluded that polyphenol-rich olive oil confers some benefits resulting in reduction of CVD-risk,
even though the authors claimed that more prolonged studies in non-Mediterranean populations were
needed to better validate the data [70].
The reported observational studies, population surveys, and randomized controlled trials on the
MD–cardiovascular health relation have been critically reviewed very recently. The study included the
five most comprehensive meta-analyses published in the 2014–2018 period together with additional
prospective studies for a total of 45 reports. The authors concluded that higher conformity to the
traditional MD matches better cardiovascular health outcomes in terms of reduced rates of coronary
heart disease, ischemic stroke, and CVD [71]. In spite of the existence of remarkable differences among
the investigated populations, the results of other studies substantially confirmed the studies reported
above and also highlighted a beneficial effect of the MD against cognitive deterioration, particularly in
AD and PD (reviewed in [72]) and against cancer. In particular, a study carried out in Australia and
New Zealand (ACTRN12613000602729) showed that a cause–effect relationship does exist between MD
and aging-dependent impairment of cognition [73]; these results were confirmed by a study carried
out with a cohort of aged people, the “Prevenciòn con Dieta Mediterrànea Nutrition Intervention
Trial” (ISRCTN35739639), where a significant improvement of cognitive behavior following MD
supplementation with olive oil or nuts was reported [74].
Several clinical studies, mostly carried out with a limited number of patients, sought to unravel
the role played by specific polyphenols in the MD against the same pathological conditions, yet with
variable results. The effects of curcumin against AD have been investigated in four clinical trials
(reviewed in [75]); two studies reported that no significant differences were found between placebo-
and curcumin-treated groups where cognition, plasma, and cerebrospinal fluid (CSF) biomarkers
were concerned [76,77]; these data were confirmed by other, more recent, trials with no solid results
on protection by lipidated curcumin against neurodegeneration in AD [78]. Over 244 clinical trials,
with an additional 27 clinical trials currently ongoing, investigated the healthy effects, safety, and
pharmacokinetics of resveratrol. Resveratrol administration gave positive results in patients suffering
from diabetes mellitus, obesity, MetS, hypertension, stroke, CVDs, colorectal and breast cancer, multiple
myeloma, AD, inflammatory diseases, and others, as summarized in a very recent review [79]. Other
clinical trials reported a positive modulation by resveratrol of enzyme systems involved in carcinogen
activation and detoxification together with some improvement of cerebral blood flow (reviewed in [80]).
Recently, a clinical trial with trans-resveratrol was conducted on 28 obese men with the MetS and
insulin resistance in the metabolic unit of the Rockefeller University Hospital. The subjects randomly
received 1 g resveratrol orally twice a day for 35 days while consuming a Western-style diet. The
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subjects were tested for glucose tolerance, energy expenditure at rest, blood pressure, and abdominal
adipose tissue. The results indicated that resveratrol altered glucose homeostasis only slightly except
in a small group of Caucasians, where it improved insulin resistance and glucose homeostasis [81].
The beneficial effects of green tea, particularly of epigallocatechins, have been largely investigated
even in clinical trials addressing their anti-cancer properties; however, the reported data do not permit
to draw solid conclusions indicating a decreased risk of breast cancer by green tea consumption, due
to the high heterogeneity of case-control and cohort studies (reviewed in [82]). Recently it has been
suggested that green tea and/or green tea extracts inhibit the progression of cardiac amyloidoses [83];
however, currently, reduced information is available in humans on the protection against amyloidoses
and amyloid-associated neurodegeneration specifically attributable to EGCG. Finally, Ginkgo biloba
extracts were administered in several clinical trials carried out in aged people, both healthy, demented,
or after ischemic stroke. Some of these studies yielded positive outcomes for what protection against
cognitive decline was concerned (reviewed in [84]). The positive effects of plant polyphenols against
breast, colon, and colorectal cancer, as emerged from clinical trials, preclinical studies, and primary
research, have been recently reviewed critically [85–88].
Clinical studies involving specific olive polyphenols are still in their infancy. In 2012, the efficacy of
an olive leaf extract as a hypoglycemic agent both in diabetic rats and in humans with improved glucose
homeostasis, reduction of fasting plasma levels of insulin and glycated hemoglobin was reported [89].
Soon after, the antidiabetic properties of this polyphenol were further supported by the results of a
randomized, placebo-controlled, crossover trial carried out with 46 middle-aged overweight men; the
study confirmed the improvement of glucose homeostasis with a reduction of glycated hemoglobin and
fasting plasma insulin levels in the enrolled patients [90]. More recently, the results of a randomized
controlled clinical trial carried out with 60 pre-hypertensive males fed for six weeks with an olive leaf
extract containing 136 mg of OLE and 6 mg of HT agreed with previous data, indicating the hypotensive
and lipid-lowering effects associated with OLE intake [91]. Olive leaf extracts also improve human
vascular function, as indicated by a randomized, double-blind, placeb-controlled, crossover trial carried
out with nine healthy males and nine healthy females on a normal diet or on a diet supplemented
with 51 mg of OLE and 10 mg of HT (four-week washout) [92]. A recent study aimed at identifying
modifications of gene and miRNAs expression following intake of high- or low-polyphenols EVOO
was carried out in 12 healthy subjects and 12 patients with the MetS by using microarray and real-time
PCR (RT-PCR). Gene and miRNAs expression analysis in PBMCs prior of after EVOO administration
showed that high-polyphenols EVOO induced modifications of the transcriptome in the investigated
cells; in particular, a number of pathways associated with pathophysiological alterations of CVDs,
metabolic diseases, and cancer were modulated. In healthy subjects, the acute intake of EVOO enriched
in polyphenols not only resulted in improved glycaemia and decreased insulin resistance, but also
modulated the transcription of genes and miRNAs involved in metabolism, inflammation, and cancer,
inducing a less severe inflammatory phenotype in peripheral blood mononuclear cells (PBMCs);
weaker effects were described in patients with the MetS as well as in healthy subjects administered
with low-polyphenol EVOO [93]. Comparable results were reported in a study where the effects
of HT on the expression of inflammation-related genes were investigated by RT-PCR in Simpson
Golabi Behmel Syndrome (SGBS) adipocytes in terms of mRNA and microRNA levels. The results
indicated that HT modulates the expression of adipocyte genes through oxidative stress reduction
and inhibition of NF-κB, thus hindering macrophage recruitment and reducing the deregulation of
signaling pathways involved in pathologies associated with obesity, with overall improvement of the
inflammatory state of the adipose tissue [94]. Another recent randomized controlled trial was carried
out with 22 healthy volunteers at post-prandial assumption of 25 g of polyphenols-enriched EVOO.
After 2 h from the intake, a significant improvement of the redox, inflammatory, and metabolic status
was detected, with decrease of oxidized LDL, malonyldialdehyde, triglicerides, and visceral adiposity
index, resulting from upregulation of superoxide dismutase 1, catalase, and upstream transcription
factor 1 [95]. Finally, a systematic review of randomized controlled trials aimed at focusing the state of
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the art of the relation between daily polyphenol consumption, circulating CVD biomarkers, and iron
level has been undertaken very recently. The reported results involved seven studies that agreed with
the inclusion criteria, and indicated that the intake of polyphenols results in a significant improvement
of the inflammatory biomarkers and lipid profile without any interference with iron levels [96].
Many other trials carried out with a number of other plant biophenols, in most cases, gave positive
outcomes against the same pathologies as those reported above. Taken together, the clinical trials data
appear encouraging, yet in the absence of definitive results on the effective benefits of the various
investigated polyphenols against a number of pathologies, and on the effective doses at which these
effects are fully reached. In particular, large clinical trials aimed at evaluating effective protection by
specific polyphenols against the most widespread neurodegenerative diseases are still lacking. In
conclusion, clinical trials and population studies support consistent and effective protection by the MD
and Asian diet, particularly associated with the prolonged intake of their polyphenols, against the
insurgence of aging-associated pathologies, notably neurodegeneration, CVDs and metabolic diseases,
and, possibly, cancer (Table 1). In particular, taking into consideration the positive results of the large
number of clinical and population studies supporting the healthy power of olive polyphenols, in
November 2011, the European EFSA authorized a claim stating the benefits of the assumption of olive
oil polyphenols, suggesting a daily intake of 5 mg (http://www.efsa.europa.eu/).




People Age Type of Study Treatment Pathology Ref
Seven Countries Study 12,763 40–59 Population,longitudinal Traditional eating CVD [46]
Lyon Diet Heart Study 605 Recur. Random. sec.prevent. trial MD Myo infarct. [47]
Three-City Study 9077 >65 Multi-centercohort study Olive oil Cognition [48]
PREDIMEDNAVARRA 1877/522 74 (mean) Observationalstudy MD/oil or nuts
CVD
risk/Cognition [49–52]
PREDIMED 447 55–80 Dietary-intervention trial Polyphenol intake
CVD
profile/cognition [51]





Nurses’ Health Study 59,930 35–65 Longitud.Associate. study Olive oil Risk of T2DM [58]
NHS II 85,157 26–45 Longitud.Associate. study Olive oil Risk of T2DM [58]
Not specified 25 unknown Cross-over study MD with EVOO Gluc./LDLchol [59]
EUROLIVE 200 various Randomizedcrossover trial EVOO
Ox.stress
mark./Chol. [60–62]
PREDIMED Study 7447 55–80 Multicenter trial MD/EVOO or nuts CVD risk [63]
Not specified 20 various Double-blindedrand. Cross. EVOO Gene express. [64]
Not specified 20 various Randomizedcrossover Olive polyphenols
Postprandial
infl. [65]
Not specified 62 65–96 Observationalstudy EVOO
Antioxidant
status [69]
Not specified 410 elderly Random.double-blind trial Ginkgo extract Dementia [68]




People Age Type of Study Treatment Pathology Ref





clinical trial MD/EVOO or nuts Cognition [74]




4 g Curcumin Cognition [76]




2/4 g Curcumin AD [77]
Trials with resveratrol - various 244 clinical trials+27 ongoing Resveratrol various [79,80]
Rockefeller Univ. Hosp. 28 various Placebo contr.Clinical trial 1g Resveratrol MetS, ins. Res. [81]
Not specified 19 various Observationalstudy Green tea extracts
ATTR
cardiomyop. [83]
Not specified - various Various Ginkgo bilobaextracts Various [84]
SUN Project 22,786 various Prospective Med.cohort study Polyphenols Breast cancer [86]
SUN Project 22,786 various Prospective Med.cohort study Polyphenols
CVD, T2DM,
MetS [97]
Not specified 79 various Controlled clinicaltrial
500 mg Olive leaf
extract T2DM [89]
Not specified 46 46.4(mean)
Randomized
crossover trial Olive leaf extract T2DM [90]





OLE + HT CVD markers [92]
Not specified 24 various Gene/miRNAsexpression
High/low polyph.
EVOO MetS [93]





4. Hormesis: A New General Concept Supporting Polyphenol Benefits
Hormesis is defined as any process in a cell or an organism characterized by a biphasic response
to the exposure to increasing amounts of a stressing condition or substance (stressor) [98]. Generally,
a favorable biological response to low exposure to any stressor is found within the hormetic zone,
whereas cell damage occurs at higher doses (Figure 2). Plant polyphenols are produced by plants to
defend themselves against pests such as bacteria, fungi, and insects, to which they are toxic. Such
toxicity is not seen in higher animals at the maximal doses so far used experimentally, reaching 10
g/day in the case of resveratrol. However, these polyphenols act as stressors to the exposed animal cells,
with the result of activating various cell defense systems aimed at controlling the redox environment,
the proteostatic and metabolic homeostasis, organelle turnover, the inflammatory response, and others,
thus making cells more resistant to subsequent toxic stimuli, particularly in aged people.
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Figure 2. Hormesis describes a biphasic dose-response feature to stressful stimuli.
In addition to many substances, including alcohol and many plant molecules, notably polyphenols,
most stressors include physical age ts and lifestyle su h as physical exercise, CR, and, possibly, mild
oxidative stress, while the role of low doses of ionizing radiations is debated. When assessed over
a broad dose–response range, all these agents display a hormetic-biphasic dose–response relation.
The biphasic dose–response results in low dose stimulation and high dose inhibition. Typically, the
highest stimulatory responses are only about 30%–60% greater than in the control group [99–101]. It is
within the low-dose stimulatory range where health benefits associated with polyphenols occur. While
maximum stimulatory responses have been shown to be highly consistent in the 30%–60% stimulatory
range, the hormetic stimulatory dose range can be quite valuable, depending on the agent, model, and
endpoint agent, with the stimulatory dose zone typically being in the 5–50-fold dose range below the
threshold. However, it is not uncommon for the stimulatory dose range to be in the 100- to 1000-fold
dose range. These quantitative features can have important public health implications since a primary
goal is to optimize the beneficial response while avoiding toxicity at higher doses. A more extensive
assessment of the occurrence of hormesis [102] and its mechanistic foundations [103] is provided in
these references. Several examples of hormetic ose responses for constituents of olive oil/olive leaf
extracts are provided i [104–107] and in Figur 3.
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Figure 3. Upper panel: Effect of luteolin on cell via ilit f endothelial (HUBEC) and MG-63
cells (adapted from [104,105]). Middle panel: Effect of ferulic acid on PC12 cell numbers using the MTT
assay (adapted from [106]). Lower panel: Effect of Herb Complex Extracts (HCE), including Olive
Leaves on Immune Responses for Cell Proliferation of Splenocytes (at 24 h) (adapted from [107]). All
graph data are reported respect to control rapresented with dotted line.
5. Plant Polyphenols Rescue Altered Homeostatic e ls
5.1. Redox Homeostasis and the Inflam atory Response
Emerging res arch as recently focused on i l i l levance for cell protection in many
degenerative diseases and for neuroprotection in several neurodegenerative disorders, particularly
AD and PD, of the redox homeostasis elicited by plant polyphenols through the activation of vitagene
signaling pathways. The latter involves redox sensitive genes such as the Hsp70, heme-oxygenase-1
(HO-1), thioredoxin/thioredoxin reductase, and sirtuins system [108]. All these cytoprotective genes
can be transcriptionally modulated by the nuclear factor erythroid 2–related factor 2 (Nrf2) as a part of
the electrophile counterattack, defined phase 2 response. Nrf2 is a key transcription effector for the
activation of wide range of cytoprotective genes (>500). The Nrf2 activity induces a mild stress response,
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providing a healthy physiological steady state and extending lifespan in different cells and animal
models. On the other hand, a chronic long-term Nrf2 stimulation may lead to pathophysiological
events, therefore the Nrf2 signaling can be considered as a hormetic-like pathway [109,110]. Increasing
evidences show that plant polyphenols activate the phase 2 response leading to the expression of various
Nrf2-dependent antioxidant vitagenes. These effects represent a powerful instrument supporting redox
homeostasis under stressful conditions [111] and support the assumptions that the helpful properties
of polyphenols carry out through adaptive stress response vitagenes. Within this context, both heme
oxygenase-1 (HO-1) and Hsp70 have received considerable attention for their recognized antioxidative
function needed to maintain cell homeostasis [112]. Moreover, the well-known principle of hormesis
may be applied also to HO-1. In fact, although several studies have shown the crucial role of HO-1
activity against oxidative and nitrosative stress [113,114], excessive upregulation of HO-1 system may
be deleterious for cells, because of accumulation of its by-products such as carbon monoxide (CO), iron,
and the bilirubin precursor, biliverdin [115]; in light of the concept of hormesis, it is reasonable to look at
these by-products of HO1 activity in terms of their positive effects obtained at very low concentrations.
As reported by Naviaux and coworkers [116], the hormetic response is activated when
chemical-physical or biological hazards surpass the cellular capacity for homeostasis. The ensuing
disruption of homeostasis induces a cascade of deleterious molecular changes in cells involving electron
flow, oxygen consumption, and redox potential, that result in alterations of cellular structures and
processes, including membrane fluidity, bioenergetics, protein folding, and misfolding. An increasing
body of evidence shows that most chronic diseases arise from the biological response to a stress factor,
not from the initial injury, or from the agent of the injury itself. The initial components of this cascade
elicit the release of ATP, ADP, metabolic intermediates of Krebs cycle, oxygen, and reactive oxygen
species (ROS) that is sustained by purinergic signaling pathway [116]. The anti-inflammatory and
resilience phenotypes arise from these initial adaptive processes eventually mediate protection from a
variety of potential injuries.
Dietary plant polyphenols that act as powerful antioxidants may block/abolish the
anti-inflammatory phenotype that results from a redox regulatory signaling pathway [117–120].
More recent findings suggest that the biphasic dose responses of hormetic type are common effects
of plant polyphenols. Interestingly, plant polyphenols are considered as a “preventive treatment of
disease” inducing biological effects with important therapeutic applications to in vitro and in vivo
models through the activation of adaptive responses [121]. Currently, increasing evidence suggests
that plant polyphenols such as curcumin, sulforaphane, resveratrol, HT, and OLE may offer beneficial
effects acting in a hormetic-like manner by activating adaptive stress-response pathways and making
the hormesis concept fully applicable to the field of nutrition. Moreover, it has been considered that
plant polyphenols may be protective through hormetic processes that involve the stress-activated
“vitagenes” [117,122].
Chronic neuroinflammation is a prominent feature shared by several neurodegenerative diseases,
such as AD and PD. Microglial activation, the hallmark of brain neuroinflammation, results in the
production of highly pro-inflammatory cytokines (i.e., TNF-α, IL-β, prostaglandin E2, cyclooxygenases,
and iNOS through the modulation of signal transduction pathways), ROS, and NO, leading to cellular
modifications including mitochondrial dysfunction, impaired energy metabolism, altered redox
homeostasis, lipid peroxidation, DNA fragmentation, neuronal inflammation, and cell death; recently,
these alterations have been associated with the pathogenesis of neurological disorders [123,124].
Inflammasomes are multiprotein signaling complexes that regulate cells of the innate immune system,
mainly microglial cells in the brain. Notably, a considerable amount of information has provided
evidence on the existence of inflammasome-mediated inflammatory pathways in neurological diseases.
In particular, the NLR family, pyrin domain-containing-3 (NLRP3) inflammasome has been shown
to play a pathogenic role in the development of neuroinflammatory disorders, such as AD [125] and
PD [126].
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In vivo and in vitro studies have highlighted a direct relationship between inflammasome
activation and AD pathogenesis, suggesting that inflammasome inhibition represents a potential
therapeutic approach for AD treatment. This concept was confirmed in APP/PS1mice (transgenic mice
with chronic deposition of Aβ) where a deficiency of NLRP3 inflammasome and caspase-1 activity were
found [127]. Moreover, in these mice models, the production of microglia with phenotype M2 induced
by NLRP3 inflammasome deficiency was observed, resulting in reduced deposition of Aβ [127]. In
addition, in humans, enhanced caspase-1 activation was found mainly in the hippocampal area of
human brain tissue of patients with AD, [127]. Moreover, in an AD mouse model, administration of
cathepsin-B (produced by microglia after Aβ phagocytosis) inhibitors significantly decreased the load
of amyloid plaques in the mouse brain tissue and resulted in substantial improvement in memory
deficit. In PD patient brains, the inflammasome pathway can potentially be activated by oxidative stress
and by insoluble α-synuclein aggregates [128]. The pathophysiological link between inflammasome
responses and Aβ-plaque spreading indicates that pharmacological targeting of inflammasomes may
represent a novel, potential treatment strategy for AD and PD.
In light of the data reported above, the activities of plant polyphenols against neuroinflammation
appear to target activated microglia resulting in low-level production of pro-inflammatory molecules
induced by the NRLP3 inflammasome. In particular, many recent data suggest the key role played
by phenolic components of EVOO in counteracting protein misfolding and proteotoxicity, with a
particular emphasis on the mechanisms leading to the onset and progression of AD and PD, including
APP processing, Aβ peptide and tau amyloid aggregation, autophagy impairment, disruption of redox
homeostasis, α-synuclein neurotoxicity, and neuroinflammation [48,72]. Additionally, several data
indicate that OLE interferes with APP processing [129] and with the amyloid aggregation of Aβ and
tau protein, escaping the growth of toxic Aβ oligomers both in vitro [17,19,130,131], in C. elegans [132],
and in TgCRND8 mice, a transgenic model of Aβ deposition [40]. In accordance with these data,
a recent study has reported that rats fed with OLE display significant improvement of cognitive
performance; in fact, OLE diet decreases the apoptosis and oxidative stress levels and prevents the
impairment of spatial learning and memory resulting from morphine-induced neurotoxicity to the
hippocampus [133].
It is noteworthy that HT, a dopamine metabolite, is present in the brain [134]. Monoamine
oxidase (MAO) catalyzes oxidative deamination of dopamine in a toxic metabolite, DOPAL
(3,4-dihydroxyphenylaldehyde), that can be oxidized by aldehyde dehydrogenase (ALDH) to DOPAC
(3,4-dihydroxyphenylacetic acid), the major metabolite of dopamine in the brainor may be reduced to
HT by alcohol dehydrogenase (ADH). At the same time, DOPAC reductase can transform DOPAC in
HT [135]. DOPAL is a highly reactive metabolite, suggesting that it might be a neurotoxic dopamine
metabolite with a role in the pathogenesis of PD [136,137].
HT removes soluble oligomeric Aβ1–42 plus ibotenic acid-induced neurobehavioral dysfunction
following intracerebroventricular injection of Aβ1–42 [130]. In hippocampal neurons, HT treatment
rescues, to a significant extent, negatively altered spatial reference and working memory induced by
Aβ, an effect associated with reduced activation of death kinases such as JNK and p38-MAPK, while
concomitantly increasing the survival-signaling pathways such as ERK-MAPK/RSK2, PI3K/Akt1, and
JAK2/STAT3 [130].
In human trials, a higher adherence to the MD was associated with reduced cognitive decline and
the risk of AD [138]. In transgenic AD mice, the positive effects of EVOO in preventing and delaying
the onset of AD and declining the severity of its symptoms have been reported [139]. However, in spite
of the reported biological effects, it has not been clear how efficiently HT acts against AD progression.
Six-month HT administration to three-month-old female transgenic APP/PS1 mice at 5 mg/kg/day
improved the electroencephalographic activity and cognitive function and reduced mitochondrial
oxidative stress and neuroinflammation [140]. Moreover, HT was shown to dose-dependently
inhibit toxicity of α-synuclein aggregation in PD [141] and HT and OLE improved spatial working
memory and energetic metabolism in the brain of aged mice [142]. Notably, HT efficiently neutralizes
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free radicals and protects biomolecules from ROS-induced oxidative damage. In this regard, HT
activates the Nrf2–antioxidant response element (ARE) pathway, leading to the activation of phase
II detoxifying enzymes and the protection of dopaminergic neurons exposed to hydrogen peroxide
or to 6-hydroxydopamine [20,143]. In addition, HT improved mitochondrial function and induced
phase II antioxidative enzymes, which decreased oxidative stress in the brain of db/db mice [144].
Recently, it has also been shown that OLE improves mitochondrial performance through activation
of the Nrf2-mediated signaling pathway protecting the hypothalamus from oxidative stress [145]. In
conclusion, HT is being considered with interest for possible use in pharmacological mitigation of
neurodegenerative processes as a potent antioxidant and a novel small molecule that can upregulate
the Nrf2-ARE pathway.
Interestingly, plant polyphenols upregulate the vitagene signaling pathway that represents a
potential therapeutic target in the crosstalk of inflammatory response process and oxidative stress in
neurodegeneration. Accordingly, recent in vitro and in vivo studies have indicated that HT attenuates
the NLRP3 inflammasome pathway by reducing pro-inflammatory interleukin (IL)-1β and IL-18
cytokine levels, oxidative stress, neuronal apoptosis, via activation of the Nrf-2/HO-1 signaling
pathway and suppression of NF-κB [146–148]. Previous research revealed that HT and OLE activate
the signaling pathway from Sirt1, an important member of the vitagene family that catalyzes the
deacetylation of various substrates, by utilizing nicotinamide (NAD+) as a substrate, to restore adaptive
homeostasis under stress conditions [149]. By regulating cellular redox homeostasis, Sirt1 plays
a critical role in neuron survival, insulin sensitivity, mitochondrial biogenesis, neurogenesis, and
inflammation [114]. Sirt1 has been shown to be essential for synaptic plasticity, cognitive functions [150],
modulation of learning, and the preservation of memory processes that deteriorate during aging, in the
brain [151]. Recently, in vitro and in vivo studies suggest that HT and OLE inhibit the inflammatory
response through different pathways regulated by several members of the sirtuin family (e.g., Sirt1,
Sirt2, Sirt6) [140,152–156].
The thioredoxin system (Trx/TrxR) is a meaningful thiol/disulphide redox controller ensuring
the cellular redox homeostasis [157,158]. In addition to the regulation of the expression of the
encoding genes, TrxR activity is also regulated post-translationally by the thioredoxin inhibitory
protein (TxNIP). In this context, a recent study has reported that HT induces neuroprotection and
cellular antioxidant defenses via upregulation of the Keap1-Nrf2-TRXR1 pathway [159]. Sulforaphane
is an herbal isothiocyanate enriched in cruciferous vegetables obtained in high concentrations from
broccoli seeds and sprouts; myrosinase, an enzyme segregated in plant cells and released when the latter
are masticated and ingested, produces sulphoraphane by glucoraphanin hydrolysis. This molecule has
been shown to be active by fostering cellular defenses against a broad spectrum of cellular stresses.
Evidence has shown that sulforaphane in the CNS activates Hsps and related mechanisms central to
multiple cellular processes, including synaptic transmission, and improves cortical connectivity [160].
In addition, sulforaphane can also decrease STAT-1 and NLRP3 inflammasome activation by the
Nrf2/HO-1 signaling pathway in human microglia-like THP-1 cells [161]. Finally, a recent in vivo study
showed that sulforaphane modulates Hsp70 upregulating C-terminus of Hsp70-interacting protein
(CHIP) and has the potential to reduce the deposition of Aβ and tau in a mouse models of AD [162].
Several studies have reported the antioxidant and anti-inflammatory properties of resveratrol,
presently under clinical trial against neurodegenerative disorders. Recent compelling evidence
indicated that resveratrol at micromolar concentrations can effectively scavenge free radicals and is an
importantallosteric activator of the vitagene signaling pathway. In addition, resveratrol is involved in
the neuroprotective mechanisms by increasing the Nrf2 pathway and reducing NF-κB activity, and
therefore exerts a positive effect against a neuroinflammatory state and counteracts the progression of
brain aging [163]. Some studies have also shown that resveratrol improves the learning and memory
deficit in neurodegenerative disorders and, through its antioxidant activity, protects against memory
decline in AD [164]. One of the major mechanisms of resveratrol as neuroprotective molecule is the
activation of Sirt1 that is expressed in the adult mammalian brain, predominantly in neurons [165].
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Moreover, resveratrol upregulates the Sirt1 pathway, thus preventing Aβ-induced microglial death and
contributing to improve cognitive function [166] and induces the SIRT-1 and TRX signaling pathways
with reduction of Aβ-stimulated NF-κB signaling, that contributes to its strong neuroprotection in
AD [167–170].
Some preclinical studies have also suggested a positive role of curcumin as an adjuvant therapeutic
strategy in free radical-based disorders, particularly neurodegenerative disorders. Some studies have
reported the key role played by HO-1 as a target for neuroprotection by curcumin [117,171]. Several
studies showed that resveratrol and curcumin increase HO-1 expression in PC12 cells and endothelial
cells, among other cell lines [168,170,172]. Moreover, it has been suggested that curcumin inhibits
IL-1β secretion and NLRP3 inflammasome activation in macrophages, reduces soluble tau oligomers,
and improves cognition by increasing HSP70, HSP90, and HSC70, in aged human tau transgenic
mice [173,174].
Taken together, all these data indicate that the activation of stress responsive mechanisms
following moderate and chronic consumption of low doses of plant polyphenols induces the vitagene
signaling pathway, thus activating antioxidant and neuroprotective cascades that could be effective to
prevent neuroinflammation in aging-associated cognitive decline, and thereby improves health-life
and longevity in animals and humans (Table 2).
Table 2. Polyphenols activity in cellular protective pathways. Activated pathways: ↑; Inactivated
pathways: ↓.
Polyphenols Anti-Oxidant Anti-Inflammatory Anti-Aggregation
Oleuropein Aglycone ↑Sirt1


























Traditionally, the main aim of nutrition is to provide correct amounts of dietary principles to
prevent and, when needed, to treat, nutritional deficiencies. However, when nutrition is inadequate
or excessive, the body faces the problem of controlling the amount of nutrients absorbed and stored,
with the ensuing emergence of diet-associated pathologies, including MetS. The latter is a complex
of symptoms and pathological conditions appearing in people over 65, particularly in females [175],
induced by insulin resistance; MetS includes T2DM, cardiovascular diseases, obesity, non-alcoholic
liver steatosis, and cancer [176]. Growing evidence indicates a significant reduction of the incidence of
T2DM and MetS by the intake of plant polyphenols [177], particularly those found in the EVOO [57,178].
MetS treatment include lifestyle modifications such as physical activity, weight control, and intake of
plant food products, such as whole grains, berries, fruits, and vegetables, all known to be sources of
many polyphenols [179,180].
The regulation of blood glucose levels is dependent on the liver, in coordination with muscle
and adipose tissue. Particularly, in the postprandial state, the liver involves several enzymes such
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as glucokinase and glycogen synthase to store glucose via the glycogenesis pathway. Moreover,
the produced glucose by the liver, via glycogenolysis or gluconeogenesis pathways, depends
by pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase, and
glucose-6-phosphatase activities [181]. In abnormal conditions, the increased post-prandial Apo-B48
levels correlate with the blood glucose levels and lipid profile [58], promoting and/or worsening the
atherosclerotic process [182]. A correlation between oxidative stress and incidence of cardiovascular
events was observed in diabetic vs. non-diabetic patients with post-prandial glycaemia [183]. Indeed,
a recent study in patients with diabetes mellitus (DM) reported a correlation between a high-fat
meal and enhanced circulating levels of gut-derived bacteria lipopolysaccharide (LPS) [184]; this
modification may represent an important activator step for systemic post-prandial oxidative stress as
LPS is responsible for activation of Nox2, a most important ROS producer [185]; overall, data obtained
in animal models and in human studies highlight the beneficial effects on postprandial blood glucose
levels of natural polyphenols derived from food fractions and beverages. It has been observed that OLE
and HT in diabetic rats modulate activities of hepatic antioxidant enzymes, superoxide dismutase, and
catalase, attenuating the oxidative stress associated with diabetes [186]. Other data reported that EVOO
consumption is associated with down-regulation of Nox-2-derived oxidative stress [187], indicating
its ability to mitigate post-prandial oxidative stress via lowering post-prandial LPS also in patients
with impaired fasting glucose [188]. Another study highlighted the different pattern of postprandial
glycaemia induced by consumption of cranberry juice sweetened with high-fructose corn syrup with
respect to comparable amount of a sweetener in water [189]. Finally, a very recent study carried out
on stroke-affected mice fed with HT-supplemented diet showed a remarkable recovery of motor and
cognitive functions, and of magnetic resonance imaging parameters, together with improvement in
neuroinflammation and neurogenesis with respect to controls mice fed with normal diet [190].
Plant polyphenols influence glucose metabolism through several mechanisms such as reduction
of intestine carbohydrate digestion and glucose absorption, stimulation of pancreatic β-cells to
secret insulin, modulation of liver glucose release, activation of insulin-sensitive tissues in terms
of insulin receptors, and glucose uptake. In this context, different polyphenols have been shown
to inhibit the enzymes involved in digestion to glucose of dietary carbohydrates, α-amylase and
α-glucosidase [180], reducing the rate of glucose release and absorption, thus suppressing post-prandial
hyperglycemia [191,192]. The polyphenols for which these inhibitory effects have been reported
include quercetin, myricetin, luteolin, EGCG theaflavin, and resveratrol [193–195]. Moreover, several
flavonoids and phenolic acids, such as tannic acids, quercetin, and myricetin, have been reported to
inhibit the sodium-dependent SGLT1 and the sodium-independent GLUT2 glucose transporters in
cultured intestinal cells [196,197]. Furthermore, it has been reported that in vitro catechins of green
tea [198], procyanidins derived from grape seed [199], bitter melon [200], phenols of EVOO [11], and
black soybean [201] act on a GLUT4-mediated process to enhance insulin-mediated glucose uptake.
Otherwise, data obtained from T2DM mice model demonstrated that black soybean seeds, rich in
anthocyanins and procyanidins, reduced glucose levels and increased insulin sensitivity activating the
PI3K and 5′-adenosine monophosphate-activated protein kinase (AMPK) pathways in the skeletal
muscle and liver [202]. Moreover, AMPK activation was also observed in OLE-treated C2C12 cells
and in high-fat-diet mice and resulted as being correlated with the up-regulation of GLUT4 in skeletal
muscle and with the down-regulation of liver gluconeogenesis [203–205]. The increased GLUT4
expression induced by OLE treatment, particularly in association with insulin, reduced oxidative stress
and enhanced glucose consumption, improving insulin sensitivity [206]. Differently, in pancreatic
β-cells, the glucose-stimulated insulin secretion resulted from glucose entrance via GLUT2, glycolysis,
and tricarboxylic acid cycle with increased ATP production and inactivation of ATP-sensitive K+
membrane channels [207]. Treatment with EGCG and buckwheat, the flavonoid rutin, resulted in
reduced glucotoxicity to β-cells by activation of insulin receptor substrate 2 (IRS2) and AMPK signaling,
and increased ATP levels [208,209]. Other data obtained with the RINmF5 cell model indicated that
polyphenols such as quercetin, apigenin, and luteolin inhibit β-cell damage through suppression of
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NF-κB activity [210]. Moreover, the glucose-stimulated insulin secretion in β-cells was promoted
by OLE treatment, but not its moiety HT, by activating ERK/MAPK signaling [211]. Other studies
reported that HT reduces the oxidative stress in adipocytes, increasing the activity of AMPK, acetyl
CoA carboxylase, hormone- sensitive lipase, and lipase phosphorylation, thus reducing the risk of
obesity, a condition that correlates positively with the MetS [209,210] (Figure 4). Many of the reported
metabolic and cellular physiologic effects elicited by plant polyphenols share a common upstream
mechanism involving AMPK activation/mTORC inhibition. The serine/threonine kinases AMPK and
mTORC are key co-ordinators and controllers of many molecular routines including those regulating
cell metabolism (anabolism or catabolism) autophagy and proteostasis, cell proliferation, and the
redox condition [210,212]. In turn, AMPK and mTORC activities are under control of several factors.
AMPK, a regulator of cellular energy homeostasis [213], is triggered by energy stress signalled by
reduced ATP and increased AMP levels [211]. AMPK is also activated by phosphorylation of two
regulatory subunits by several kinases, including the energy stress-sensitive LKB [214], PKA [215],
and the CAMM-GSK3β axis [216] as well as by other factors, including PPARα, associated with lipid
metabolism [217] and hypoxia [218]. AMPK triggers the expression of antioxidant enzymes, notably
HO-1, through Nrf2 [219,220], and improves the control of proteostasis [221] through direct activation
of FOXO3 [222] and ULK1 [223] and by indirect activation of TFEB [224]; AMPK activation also
improves both glucose metabolism by favoring GLUT4 translocation to the membrane [225,226] and
lipid metabolism through PPARα. Finally, AMPK activation results in inhibition of mTORC following
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Some of the mechanisms reported above are also triggered by plant polyphenols. In particular,
it has been reported that OLE increases intracellular free Ca2+ levels from the internal stores with
ensuing activation of the calcium-CAMMK-GSK3β pathway [216] and reduces oxidative stress through
Int. J. Mol. Sci. 2020, 21, 1250 19 of 40
AMPK-dependent activation of HO-1 [219], whereas in aged rats, resveratrol protects against high-fat
diet-induced muscle atrophy counteracting PKA/LKB1/AMPK-mediated mitochondrial dysfunction
and oxidative stress [215]. Finally, plant polyphenols including quercetin, resveratrol, and catechins
activate SIRT1, a class-3 histone deacetylase involved in several aging-related pathologies, including
neurodegeneration [228]. Recent data with TgCRND1 mice indicate that SIRT1 is activated by OLE,
with concomitant inhibition of PARP1 in a crosstalk affecting apoptosis and autophagy [40]. It is
remarkable that some of these effects by several plant polyphenols are shared with the well-known
antidiabetic drug metformin [229]. These molecules have different ways of accomplishing their
functions and work in different cell types; however, taken together, the vast amount of research and
preclinical data provide a convincing, yet still incomplete, explanation of the cellular protection by
these substances that underlies their hormetic behaviour (see Figure 4).
5.3. Proteostasis
Proteostasis is a key biological process under strict cellular control by maintaining the equilibrium
between protein synthesis and protein degradation by different protein degradation machineries (the
chaperone–ubiquitin–proteasome and various forms of autophagy), whose homeostasis is needed for
a healthy life span. The proteostasis network needs the coordinated action of both chaperones and the
ubiquitin–proteasome system (UPS), and several types of autophagy, notably macro-autophagy and
chaperone-mediated autophagy. Molecular chaperones, in particular the heat shock proteins (HSPs),
are the prime line of defense to counteract protein misfolding and the ensuing protein deposition;
they recognize hydrophobic regions of proteins and promote either their refolding or their transfer to
the UPS or autophagy systems [230]. The small HSPs are ATP-independent chaperones, a particular
class of HSPs that bind misfolded and aggregation-prone proteins, avoiding undesired intermolecular
interactions and preventing their aggregation with ensuing loss of function [231,232]. The UPS is
localized both in the cytoplasm and in the nuclei; it provides rapid degradation of proteins following
their polyubiquitination and subsequent delivery to the proteasome. The misfolded proteins of
the secretory pathway are managed by the endoplasmic reticulum-associated protein degradation
(ERAD) pathway.
Differently from the UPS and the ERAD pathways, autophagy, a self-digestive process triggered
by nutrient deprivation, aging, and other stressful conditions including energy shortage, heath shock,
and oxidative stress, is important for long-lived proteins and organelles clearance. It requires the
participation of a number of proteins encoded by autophagy-related genes (Atg) that are necessary to
the formation of autophagosomes, double membrane vesicles, where the cargo material is engulfed and
their subsequent delivery to lysosomes for degradation [233]. In addition to the proteostasis network,
the cells can also alleviate intracellular accumulation of misfolded proteins through a selective secretion
of damaged proteins and RNAs into vesicles of endosomal origin, called exosomes. Several evidences
have stressed a crosstalk between the autophagic pathway and the exososomes [234].
The proteostasis network can decline permanently or transiently following development, aging,
and exposure to environmental stress, and this decline may contribute to adult-onset proteotoxic
disorders and their progression. In particular, a continuous reduction of the efficiency of the proteostasis
network may induce pathological aging with accumulation of abnormal proteins, a common feature
of many oncological, neurodegenerative, metabolic, and cardiovascular disorders. Proteostasis
deregulation at the level of the ER is one of the major contributors to aging and cancer as well [235].
Indeed, harmful stimuli, such as oxidative stress and disruptions of the secretory process may contribute
to deposition of unfolded or misfolded proteins at the ER lumen, thus upregolating the endoplasmic
reticuluym (ER) stress response [236]. Finally, cancer cells accumulate genetic changes resulting in the
presence of mutated proteins; accordingly, most cancer cells are closely dependent on the proteostasis
network for survival.
Scientific evidence shows that natural molecules, such as polyphenols, exhibit healthy and
protective effects as consequence of their ability not only to maintain the proper oxidant/antioxidant
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balance in cells, but also for their anti-inflammatory power together with their ability to control the
activity of signaling pathways responsible with cell survival, proliferation, and migration. Moreover,
the pleiotropic anti-amyloid properties of the polyphenols indicate that these molecules may be useful
for treatment of several amyloidosis, notably T2DM and several neurodegenerative diseases. Indeed,
many plant polyphenols can reduce the aggregation of some proteins/peptides involved in metabolic
and neurodegenerative diseases and can directly or indirectly enhance the clearance of misfolded
proteins by modulating the activity of the proteostasis network. However, recent data indicate that
increased efficiency of proteostasis and stress resistance may also favor cancer progression. The
stresses accomplished by cancer cells require active chaperone platforms to limit protein misfolding
and aggregation; the latter, in these cells, may result from high levels of protein synthesis and metabolic
requests, oxidative stress, growth under hypoxic and acidic conditions, and protein expression in
altered stoichiometries resulting from aneuploidy [237]. The modulation of the proteostasis network by
small regulatory molecules can provide a previously unexploited and potentially powerful approach
to improve proteome balance.
Resveratrol, one of the most investigated plant polyphenols, displays eclectic biochemical behavior;
in fact, it acts upstream of several signaling cascades, likely upon binding to membrane receptor(s);
actually, potential binding sites were detected in the plasma membrane of neuronal cells and, to a lesser
extent, in nuclear and cellular fractions of rat brain homogenates [238]. In addition, resveratrol mimics
some aspects of the CR by inhibiting cAMP phosphodiesterase with activation of AMPK, with reduced
fat accumulation, increased glucose tolerance, insulin sensitivity, mitochondrial biogenesis, and physical
endurance. Besides its antioxidant activity [239], resveratrol reduces both intracellular and secreted
Aβ in cell culture by activating chaperones such as Hsp70 and by inducing proteasome-dependent Aβ
degradation [240]. In addition, resveratrol activates SIRT-1, increases AMPK activity, thus reducing
Aβ-induced death signals, such as NF-κB signaling and p53 activity [240] and triggering the degradation
of Aβ aggregates by autophagy [239]. The anti-cancer property of resveratrol occurs by inducing
caspase 8- and caspase 3-dependent apoptosis via ROS-induced autophagy in human colon cancer
cells [241]. In androgen-independent prostate cancer cells, resveratrol induces autophagy-mediated
cell death through regulation of store-operated Ca2+ entry (SOCE) mechanisms, and down-regulation
of stromal interaction molecule 1 (STIM1) expression. In addition, resveratrol triggers ER stress by
depleting the pool of ER calcium [242]. Resveratrol has also been shown to decrease the proliferation of
breast cancer stem-like cells by inhibiting Wnt/β-catenin signaling pathway [243]. Finally, resveratrol
has been shown to act as an inhibitor of global protein synthesis in the H4-II-E rat hepatoma cell
line. This effect was reached through modulation of mTOR self-phosphorylation and hence of
mTOR-dependent and mTOR-independent signaling by reduced formation of the eIF4F translation
initiation complex and increased phosphorylation of eIF2α with inhibition of translation [244]. Other
findings in renal tissues of rats fed with resveratrol after unilateral uretral obstruction point to the
reduced expression of eIF2α and the ensuing reduced levels of ATF4 [245].
Other plant polyphenols have been investigated for their ability to control the proteostasis system
at several levels. Curcumin displays several beneficial effects in different in vivo models of aging,
ischemia, trauma, and neurodegeneration. In in vivo models of proteinopathies, curcumin reduces
plaque burden and improves cognitive function [246]. In addition, curcumin has been shown to
induce the expression of Hsp genes and the nuclear translocation of Hsf1, a master regulator of
Hsp expression [247]. Green tea catechins show conformational similarities to chaperones and a
chaperone-like activity [248]. Phenolic and flavonoid components present in bee pollen activate the
chymotrypsin-like activity of the proteasome in HFL-1 human embryonic fibroblasts [249]. OLE
displays neuroprotection by increasing proteasome activity, and extending the life span of human
IMR90 and WI-38 embryonic fibroblasts [250]. The administration of OLE to the C. elegans C2006
strain expressing Aβ42 in muscle cells induced a significant reduction of amyloid plaque and toxic
oligomer formation, with reduction of the extent of paralysis and increased lifespan [132]. The dietary
administration of OLE also improved the cognitive performance of the TgCRND8 mouse model of
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Aβ deposition resulting from reduced plaque deposits, increased microglia migration to the plaques
for phagocytosis, and an intense autophagic reaction followed by modulation of the mTOR/AMPK
pathways [14,40]. Recent data with cardiomyocytes indicate that OLE counteracts MAO-A cytotoxicity
and that this effect results from restoration of restoration of the defective autophagic flux, as indicated by
the increase of autolysosomes, indicative of autophagosome–lysosome fusion. Interestingly, autophagy
induction involved nuclear translocation and activation of the master gene for lysosomal biogenesis
TFEB, suggesting a role of OLE as a TFEB activator [251].
Quercetin has been shown to have neuroprotective effect in various in vitro and in vivo systems.
In malignant mesothelioma, quercetin inhibits cell growth and increases the levels of Nrf2, with the
transcriptional activation of genes involved in the control of the cellular redox status [252]. In addition,
quercetin may induce the expression of chaperones and of proteasome subunits through the Nrf2
pathway [253]. In primary effusion B cell lymphoma, quercetin induces apoptosis and autophagy by
inhibiting the PI3K/AKT/mTOR and STAT3 signaling pathways, with the ensuing down-regulation of
the expression of pro-survival cellular proteins such as c-FLIP, cyclin D1, and cMyc [254].
6. Epigenetic Implications
The pivotal mechanisms of genetic regulation, that induce or repress the expression of genes,
include genetic mutations and epigenetic modifications, the last include DNA methylation, histone
acetylation, methylation or phosphorylation, and RNA interference (RNAi). When aberrant, these
modifications influence the onset and worsening of diseases and these alterations are considered as
essential hallmarks for distinct types of cancer, neurodegenerative diseases, metabolic disorders, bone,
and skeletal diseases [2]. In principle, drugs are able to reverse epigenetic defects on the contrary to
genetic alterations [255]. In this regard, promising results for cancer treatment have been obtained
from two groups of drugs with inhibitory activities on DNA methyl transferase (DNMT) and histone
deacethylase (HDAC) [256]. Recently, most studies demonstrated epigenetic modifications induced
by natural polyphenols treatment, allowing the introduction of the term “epigenetic diet” [257–259].
As an example, several polyphenols, including curcumin, resveratrol, and catechins, are reported to
act on the NF-κB expression and chromatin remodeling through modulation of HDACs and DNMTs
activity [260] (Figure 5). Below, several studies supporting plant polyphenols effects on epigenetic are
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6.1. DNA Methylation
The presence or the absence of 5-methylcytosine define DNA methylated regions of DNA template.
The methylation on cytosine residues depends on DNMTs or 10 or 11 translocation methyl-cytosine
dioxygenases (TETs) activity. In this way, the gene expression is regulated by DNA methylation in a
region-specific manner, and occurs predominantly at cytosines preceding a guanine nucleotide (CpG
sites). Usually, DNA hypermethylation occurs at promoter CpG islands and is a major epigenetic
mechanism to silence gene expressions [261]. However, at present, the methylation process must
establish a relationship between of intronic, exonic, or untranslated regions and the expression pattern
of the encoded proteins [262]. The acetylation and methylation mechanisms reverse the epigenetic
modifications of genes that include chemical modification, e.g., the methylation at CpG dinucleotides,
and the ensuing transcriptional activation of histone complexes [263]. The DNA methylation of some
developmental genes is a highly controlled mechanism that involved the NAD-dependent deacetylase
SIRT1 that selectively prevents abnormal methylation process [264]. Sirtuins, NAD+-dependent
enzymes, are considered amongst the most promising anti-aging targets, leading to define these
deacetylases as “the enzymes of youth”. Sirtuins depend on AMPK via stimulation of nicotinamide
phosphoribosyltransferase (NAMPT), an enzyme involved in NAD+ synthesis that regulates cellular
metabolism in several mammalian organs and tissues [265] and whose inhibition worsens diet-induced
hepatic steatosis in mice [266].
Recent studies have provided a lot of data to support that plant polyphenols and other
phytochemicals remarkable impact on DNA methylation by causing direct or indirect modifications
of DNMTs levels and activity. For example, genistein, one of the phytoestrogens found in soybeans,
reduces DNMT activity, forming a complex with it, and activates tumor suppressor genes, with possible
significance for cancer prevention and therapy [267]. Other data indicate that resveratrol activates
both the PGC1α/SIRT1/AMPK axis and DNMTs, with beneficial effects for cancer prevention and
treatment [268]. Similar results have been reported for quercetin [269] and EVOO polyphenols; the
latter were shown to activate the Sirt1 path, with possible relevance for AD prevention/treatment [40].
Furthermore, studies performed on esophageal, oral, skin, regulatory T-cells, lung, breast, and prostate
cancer cells reported alterations induced by bioactive compounds from green tea, including EGCG, on
DNMT activity in studies performed on esophageal, oral, skin, regulatory T-cells, lung, breast, and
prostate cancer cells [270]. In detail, Fang et al. suggested an EGCG inhibitory effect on DNMT and
reactivation of methylation-silenced genes in human colon, esophageal, and prostate cancer cells [271].
Finally, it appears that the inhibition of DNMT is a chemopreventive effect on cancer cell growth by
genistein, suggesting its use as anti-neoplastic drug in some malignancies [272].
6.2. Histone Modifications
The primary components of the epigenome are the post-translational modifications (PTMs) of
histones often leading to charge-induced changes in the nucleosome, with major influence on gene
expression. Histone PTMs also regulate several biological processes by chemical alterations of chromatin
and the ensuing modulation of gene expression that contributes significantly to aging-associated
dysfunctions and to tumor development and carcinogenesis [273]. Histone modifications can result
from the activity of various enzymes, including histone acetyltransferases (HATs), histone deacetylases
(HDACs), histone methyltransferases (HMTs), and histone demethylases (HDMs). The histone
acetylation is a process involved in the regulation of different cellular processes such as transcription,
gene silencing, apoptosis, DNA repair, and cell differentiation [274]. Differently, HDACs catalyze
histone de-acetylation, signal transduction, apoptosis, and cell growth [275].
As modulators of histone modifications, many dietary polyphenols hold promise to be effective for
prevention and therapy of neurodegeneration and some cancers. For example, the inhibition of HDAC
activity is due to the interaction between sulforaphane complexes with the active sites of HDACs [276].
EGCG not only modifies DNA methylation, but also acts as a histone modifier, interfering with the
HDAC and HAT activities [277]. Quercetin behaves as an HAT inhibitor and suppresses HAT activity
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in human endothelial cells [278]; moreover, a recent study suggests that it can also inhibit HDAC [279].
Recently, it has been reported that the co-treatment with suberoylanilidehydroxamic acid (SAHA), an
HDAC inhibitor, and naringenin, a flavone present in citrus, synergistically induces cytotoxic effects in
neuroblastoma with respect to non-malignant neuronal cells [280]. Genistein is the polyphenol with
the highest ability to modify histone activity compared to other isoflavones; indeed, it was reported an
increased HATs and decreased HDACs activity after treatment with this compound of precancerous
and cancer breast cells [281–283]. Otherwise, clinical benefits in cancer cells have been obtained after
curcumin treatment, resulting in down-regulation of HATs activity [284].
Recent data indicate that the protective effects of OLE in the diet of a Tg murine model of Aβ
deposition could be traced bask, at least in part, to the increased acetylation of histone 3 and 4, that
matched the reduced expression of HDAC-2 [40], whose levels are increased in the AD brain [285,286]
and of glutaminyl cyclase (GC), the enzyme responsible for the generation of pE3Aβ, the most
aggregating pyroglutamylated derivative of the Aβ1–42 peptide in AD [287]. Interestingly, GC is
significantly increased in the brain of AD patients [288]. Similar epigenetic effects have been reported
in cancer cells [289]. Oleacein, another EVOO polyphenol, also induces a strong increase of histone
and α-acetyl-tubulin acetylation [290].
6.3. Noncoding RNAs
MicroRNAs (miRNAs) are small non-coding RNA molecules, 20–22 nucleotides in length,
organized in a single-strand structure, with the function of RNA silencing and post-transcriptional
regulation of gene expression [291]. miRNAs significantly participate in epigenetic regulation;
in fact, they perform catalytic functions related to RNA splicing and significantly contribute to
post-translational gene regulations. Accordingly, miRNAs regulate many cellular processes, including
cell proliferation, apoptosis, cell differentiation, and any alterations of their expression correlate
with different disease progression. Many studies support a direct association between alterations
of miRNAs expression and cancer [292]. Indeed, bladder, lung, and breast cancer onset correlates
with different mechanisms of regulation of miRNAs expression including chromosomal abnormalities,
single nucleotide polymorphisms (SNPs), mutations in primary transcripts [293], altered activity of
transcription factors, such as the miR-17-92 cluster, and modifications in the miR-34 family such as
consequence of p53 activation [294,295].
Recently, EGCG has been found to decrease the expression of oncogenic miRNAs (miR-92, miR-93,
and miR-106b) and to increase the expression of tumor-suppressor miRNAs (miR-7-1, miR-34a, and
miR-99a) in human cancer cells [296,297]. Another study in apolipoprotein E-deficient mice reported
that the treatment with one of nine different polyphenols including hesperidin and naringenin affected
the expression of five miRNA in vivo [298]. Curcumin also regulates pancreatic cancer symptoms
by up-regulation of miR-22 and down-regulation of miR-199a [299]. However, the potential use of
curcumin and other polyphenols against cancer cells trough modulation of miRNAs is very prominent,
but at the same time, limited because of the reduced bioavailability of these substances. In spite of these
limitations, the data currently available contribute to explaining the healthy effects of flavonones [298].
7. Conclusions
A growing number of population surveys and clinical trials increasingly support the use of
plant polyphenols, possibly in association with more specific drugs, to prevent and/or to treat several
aging-associated pathologies [300]. However, in a number of cases, contradictory results have been
reported possibly due to different experimental settings in terms of dose, length of treatment, clinical
conditions of the enrolled patients at the onset of treatment, and other unknown variables. In fact,
the low bioavailability of polyphenols must be taken into account, as well as the fact that the latter
could be further affected by specific physiological features of different patients, also taking into
account the role played by the gut microbiota. Moreover, data are still lacking that properly focus the
pharmacodynamics and pharmacokinetics of these molecules in different clinical settings. However,
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the overall picture that emerges from the body of the data currently available strongly suggests the
nutraceutical value of these substances, yet with differences from each other.
The positive results arising from population surveys and clinical trials are increasingly supported
at the molecular/cellular/tissue level by the large body of studies carried out recently that have, at least
in part, unraveled the molecular basis and the cellular correlates of the healthy effects recorded at the
organismal level. What emerges from these studies is the ability of plant polyphenolsthese to interact
with many regulatory molecules modulating a number of signaling paths that maintain proteostasis
as well as the redox and metabolic homeostasis or restore any disequilibrium of these conditions. In
this sense, the data on the modulation of several epigenetic modifications by some of these molecules,
although still limited, are of importance, providing clues as to how plant polyphenols can produce so
many heterogeneous effects at the cellular level, integrating and extending the hormetic theory.
In conclusion, the rising interest in the nutraceutical/pharmacological exploitment of plant
polyphenols or their molecular scaffolds holds promise that in the near future, the knowledge of
the molecular/cellular determinants of the beneficial effects of these molecules, together with their
pharmacokinetics and pharmacodynamics, will increase. It is also expected that results from more
extended and convincing clinical trials will be reported, better focusing on benefits and, possibly, caveats
associated with the use of these molecules or their chemical derivatives. Such increased information,
provided it will further confirm the potential of plant polyphenols in the prevention/treatment of
metabolic-, aging-, or lifestyle-associated pathologies presently without resolutive therapies, will allow
a more general use of these molecules as an important tool to prevent or to reduce the incidence of
these increasingly widespread pathologies, ensuring safer aging.
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